AU2015358384B2 - Kinase inhibitor prodrug for the treatment of cancer - Google Patents

Kinase inhibitor prodrug for the treatment of cancer Download PDF

Info

Publication number
AU2015358384B2
AU2015358384B2 AU2015358384A AU2015358384A AU2015358384B2 AU 2015358384 B2 AU2015358384 B2 AU 2015358384B2 AU 2015358384 A AU2015358384 A AU 2015358384A AU 2015358384 A AU2015358384 A AU 2015358384A AU 2015358384 B2 AU2015358384 B2 AU 2015358384B2
Authority
AU
Australia
Prior art keywords
cancer
egfr
compound
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015358384A
Other languages
English (en)
Other versions
AU2015358384A1 (en
Inventor
Matthew Roy BULL
Nipun Davar
Christopher Paul Guise
Victoria JACKSON
Adam Vorn Patterson
Tillman PEARCE
Shevan SILVA
Jeffrey Bruce Smaill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of AU2015358384A1 publication Critical patent/AU2015358384A1/en
Application granted granted Critical
Publication of AU2015358384B2 publication Critical patent/AU2015358384B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015358384A 2014-12-03 2015-12-03 Kinase inhibitor prodrug for the treatment of cancer Active AU2015358384B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462087212P 2014-12-03 2014-12-03
US62/087,212 2014-12-03
US201562150729P 2015-04-21 2015-04-21
US62/150,729 2015-04-21
US201562167849P 2015-05-28 2015-05-28
US62/167,849 2015-05-28
US201562187750P 2015-07-01 2015-07-01
US62/187,750 2015-07-01
PCT/US2015/063806 WO2016090174A1 (en) 2014-12-03 2015-12-03 Kinase inhibitor prodrug for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2015358384A1 AU2015358384A1 (en) 2017-06-29
AU2015358384B2 true AU2015358384B2 (en) 2021-03-04

Family

ID=56092487

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015358384A Active AU2015358384B2 (en) 2014-12-03 2015-12-03 Kinase inhibitor prodrug for the treatment of cancer

Country Status (6)

Country Link
US (1) US10507210B2 (cg-RX-API-DMAC7.html)
EP (1) EP3226869A4 (cg-RX-API-DMAC7.html)
JP (1) JP6769962B2 (cg-RX-API-DMAC7.html)
CN (2) CN107427515B (cg-RX-API-DMAC7.html)
AU (1) AU2015358384B2 (cg-RX-API-DMAC7.html)
WO (1) WO2016090174A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7030066B2 (ja) 2016-05-26 2022-03-04 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Ｅｇｆｒ阻害剤化合物
FI3583943T3 (fi) * 2017-02-15 2024-10-29 Taiho Pharmaceutical Co Ltd Farmaseuttinen koostumus
KR20200072478A (ko) 2017-09-08 2020-06-22 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 Her-구동된 약물-내성암의 치료 또는 예방을 위한 화합물, 조성물 및 방법
WO2019049956A1 (ja) 2017-09-08 2019-03-14 大鵬薬品工業株式会社 抗腫瘍剤及び抗腫瘍効果増強剤
EP3681498B1 (en) * 2017-09-14 2022-10-05 Lankenau Institute for Medical Research Methods and compositions for the treatment of cancer
WO2019125184A1 (en) * 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
WO2020055643A2 (en) * 2018-09-04 2020-03-19 Rain Therapeutics Inc. Compounds, compositions and methods for treating or preventing her-driven cancers
WO2020084347A2 (en) * 2018-10-26 2020-04-30 Auckland Uniservices Combination of a kinase inhibitor and an immunotherapeutic agent, compositions and methods comprising the same
WO2020102304A1 (en) * 2018-11-13 2020-05-22 Rain Therapeutics Inc. Combination of a kinase inhibitor and an electrolyte, compositions and methods comprising the same
WO2020118251A2 (en) * 2018-12-07 2020-06-11 The Board Of Trustees Of The Leland Stanford Junior University Hypoxia targeting compositions and combinations thereof with a parp inhibitor and methods of use thereof
JOP20210233A1 (ar) 2019-02-26 2023-01-30 Janssen Biotech Inc علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011028135A1 (en) * 2009-09-02 2011-03-10 Auckland Uniservices Limited Kinase inhibitors, prodrug forms thereof and their use in therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
JPH09507121A (ja) 1993-10-26 1997-07-22 アフィマックス テクノロジーズ ナームロゼ ベノートスハップ 生物学的チップ上の核酸プローブアレー
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
JP2000504575A (ja) 1996-02-08 2000-04-18 アフィメトリックス，インコーポレイテッド 微生物のチップベースの種分化および表現型特徴付け
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
MY183041A (en) * 2008-05-13 2021-02-08 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- {[1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
CN105541836A (zh) 2009-03-11 2016-05-04 奥克兰联合服务有限公司 激酶抑制剂的前药形式及其在治疗中的用途
US20130288240A1 (en) * 2010-05-21 2013-10-31 Cell Signaling Technology, Inc. Alk and ros kinase in cancer
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
DK3686194T3 (da) * 2011-07-27 2021-11-22 Astrazeneca Ab 2-(2,4,5-substitueret-anilino)pyrimidinforbindelser
HUE041499T2 (hu) * 2012-11-21 2019-05-28 Janssen Biotech Inc Bispecifikus EGFR/C-MET-ellenanyagok
AU2014229468A1 (en) * 2013-03-14 2015-09-03 Pfizer Inc. Combination of an EGFR T790m inhibitor and an EGFR inhibitor for the treatment of non-small cell lung cancer
US20160296538A1 (en) 2013-04-10 2016-10-13 Threshold Pharmaceuticals, Inc. Predictive and response biomarker for th-302 anti-cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011028135A1 (en) * 2009-09-02 2011-03-10 Auckland Uniservices Limited Kinase inhibitors, prodrug forms thereof and their use in therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
<URL:http://www.mauricewilkinscentre.org/news/local-cancer-drug-approved-for-first-clinical-trial-in-united-states-and-new-zealand.aspx> *
<URL:https://www.fmhs.auckland.ac.nz/en/faculty/about/news-and-events/news/2012/08/30/local-cancer-drug.html> *
PATTERSON A.V. et al. 'PR610: A novel hypoxia selective tyrosine kinase inhibitor in phase 1 clinical trial.', Molecular Cancer Therapeutics (2013) Vol.12 Suppl 1., Abstract: B278 *
'View of NCT01631279 on 2013_10_15', ClinicalTrials.gov archive, published 15 October 2013, (online), [retrieved from internet on 23 February 2016]. <URL:https://clinicaltrials.gov/archive/NCT01631279/2013_10_15> *

Also Published As

Publication number Publication date
US10507210B2 (en) 2019-12-17
EP3226869A1 (en) 2017-10-11
CN107427515A (zh) 2017-12-01
CN107427515B (zh) 2021-11-16
WO2016090174A1 (en) 2016-06-09
JP2017536408A (ja) 2017-12-07
AU2015358384A1 (en) 2017-06-29
US20170360790A1 (en) 2017-12-21
CN114224894A (zh) 2022-03-25
CN114224894B (zh) 2025-01-07
EP3226869A4 (en) 2018-07-18
JP6769962B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
AU2015358384B2 (en) Kinase inhibitor prodrug for the treatment of cancer
Amaravadi et al. Recent insights into the function of autophagy in cancer
Russo et al. Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going
JP6970217B2 (ja) ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ
US11707463B2 (en) FGFR2 inhibitors for the treatment of cholangiocarcinoma
US9295676B2 (en) Mutation mimicking compounds that bind to the kinase domain of EGFR
US20240075042A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
Ichihara et al. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations
Mellinghoff et al. Isocitrate dehydrogenase mutant grade II and III glial neoplasms
WO2022087018A1 (en) Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer
TW202406552A (zh) 用於治療癌症之ｅｇｆｒ抑制劑
US20220054484A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
Waring The Discovery of Osimertinib (TAGRISSO™): An Irreversible Inhibitor of Activating and T790M Resistant Forms of the Epidermal Growth Factor Receptor Tyrosine Kinase for the Treatment of Non‐Small Cell Lung Cancer
US12263173B2 (en) PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
US20250275978A1 (en) Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer
WO2025232765A1 (en) Treatment of cancer with pyrimidoheterocyclic compounds
US20240000791A1 (en) Methods of Using 4-Amino-N-[4-(Methoxymethyl)Phenyl]-7-(1-Methylcyclopropyl)-6-(3-Morpholinoprop-1-YN-1-YL)-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carboxamide for the Treatment of Tumors
Schöffski et al. BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study
CN107405348A (zh) Raf抑制剂与紫杉烷的组合
EP3852756A1 (en) Treatment of cholangiocarcinoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)